188 related articles for article (PubMed ID: 33243933)
1. PODO447: a novel antibody to a tumor-restricted epitope on the cancer antigen podocalyxin.
Canals Hernaez D; Hughes MR; Dean P; Bergqvist P; Samudio I; Blixt O; Wiedemeyer K; Li Y; Bond C; Cruz E; Köbel M; Gilks B; Roskelley CD; McNagny KM
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33243933
[TBL] [Abstract][Full Text] [Related]
2. Targeting a Tumor-Specific Epitope on Podocalyxin Increases Survival in Human Tumor Preclinical Models.
Canals Hernaez D; Hughes MR; Li Y; Mainero Rocca I; Dean P; Brassard J; Bell EM; Samudio I; Mes-Masson AM; Narimatsu Y; Clausen H; Blixt O; Roskelley CD; McNagny KM
Front Oncol; 2022; 12():856424. PubMed ID: 35600398
[TBL] [Abstract][Full Text] [Related]
3. A tumor-restricted glycoform of podocalyxin is a highly selective marker of immunologically cold high-grade serous ovarian carcinoma.
Brassard J; Hughes MR; Dean P; Hernaez DC; Thornton S; Banville AC; Smazynski J; Warren M; Zhang K; Milne K; Gilks CB; Mes-Masson AM; Huntsman DG; Nelson BH; Roskelley CD; McNagny KM
Front Oncol; 2023; 13():1286754. PubMed ID: 38188285
[TBL] [Abstract][Full Text] [Related]
4. PcMab-47: Novel Antihuman Podocalyxin Monoclonal Antibody for Immunohistochemistry.
Ogasawara S; Kaneko MK; Yamada S; Honma R; Nakamura T; Saidoh N; Yanaka M; Yoshida K; Fujii Y; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Apr; 36(2):50-56. PubMed ID: 28384052
[TBL] [Abstract][Full Text] [Related]
5. A Cancer-Specific Monoclonal Antibody against Podocalyxin Exerted Antitumor Activities in Pancreatic Cancer Xenografts.
Suzuki H; Ohishi T; Tanaka T; Kaneko MK; Kato Y
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203331
[TBL] [Abstract][Full Text] [Related]
6. Epitope Mapping of a Cancer-Specific Anti-Podocalyxin Monoclonal Antibody (PcMab-60) Using Enzyme-Linked Immunosorbent Assay and Surface Plasmon Resonance.
Asano T; Suzuki H; Kaneko MK; Kato Y
Monoclon Antib Immunodiagn Immunother; 2021 Oct; 40(5):227-232. PubMed ID: 34678093
[TBL] [Abstract][Full Text] [Related]
7. Antipodocalyxin Antibody chPcMab-47 Exerts Antitumor Activity in Mouse Xenograft Models of Colorectal Adenocarcinomas.
Kaneko MK; Kunita A; Yamada S; Nakamura T; Yanaka M; Saidoh N; Chang YW; Handa S; Ogasawara S; Ohishi T; Abe S; Itai S; Harada H; Kawada M; Nishioka Y; Fukayama M; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Aug; 36(4):157-162. PubMed ID: 28665782
[TBL] [Abstract][Full Text] [Related]
8. Anti-Podocalyxin Monoclonal Antibody 47-mG
Yamada S; Itai S; Kaneko MK; Kato Y
Monoclon Antib Immunodiagn Immunother; 2018 Apr; 37(2):91-94. PubMed ID: 29649375
[TBL] [Abstract][Full Text] [Related]
9. Podocalyxin enhances breast tumor growth and metastasis and is a target for monoclonal antibody therapy.
Snyder KA; Hughes MR; Hedberg B; Brandon J; Hernaez DC; Bergqvist P; Cruz F; Po K; Graves ML; Turvey ME; Nielsen JS; Wilkins JA; McColl SR; Babcook JS; Roskelley CD; McNagny KM
Breast Cancer Res; 2015 Mar; 17(1):46. PubMed ID: 25887862
[TBL] [Abstract][Full Text] [Related]
10. 47-mG
Kaneko MK; Itai S; Yamada S; Kato Y
Monoclon Antib Immunodiagn Immunother; 2018 Jun; 37(3):158-161. PubMed ID: 29630446
[TBL] [Abstract][Full Text] [Related]
11. Sialofucosylated podocalyxin is a functional E- and L-selectin ligand expressed by metastatic pancreatic cancer cells.
Dallas MR; Chen SH; Streppel MM; Sharma S; Maitra A; Konstantopoulos K
Am J Physiol Cell Physiol; 2012 Sep; 303(6):C616-24. PubMed ID: 22814396
[TBL] [Abstract][Full Text] [Related]
12. Antibody-Drug Conjugates Targeting Tumor-Specific Mucin Glycoepitopes.
Brassard J; Hughes MR; Roskelley CD; McNagny KM
Front Biosci (Landmark Ed); 2022 Nov; 27(11):301. PubMed ID: 36472102
[TBL] [Abstract][Full Text] [Related]
13. Ubiquitous yet distinct expression of podocalyxin on vascular surfaces in normal and tumor tissues in the rat.
Testa JE; Chrastina A; Li Y; Oh P; Schnitzer JE
J Vasc Res; 2009; 46(4):311-24. PubMed ID: 19142011
[TBL] [Abstract][Full Text] [Related]
14. A cancer-specific anti-podocalyxin monoclonal antibody (60-mG
Kaneko MK; Ohishi T; Kawada M; Kato Y
Biochem Biophys Rep; 2020 Dec; 24():100826. PubMed ID: 33088928
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies specific for podocalyxin expressed on human induced pluripotent stem cells.
Watanabe T; Kakuta J; Saito S; Hasehira K; Kiyoi K; Imai T; Tateno H
Biochem Biophys Res Commun; 2020 Nov; 532(4):647-654. PubMed ID: 32912628
[TBL] [Abstract][Full Text] [Related]
16. Podocalyxin enhances the adherence of cells to platelets.
Larrucea S; Butta N; Rodriguez RB; Alonso-Martin S; Arias-Salgado EG; Ayuso MS; Parrilla R
Cell Mol Life Sci; 2007 Nov; 64(22):2965-74. PubMed ID: 17922228
[TBL] [Abstract][Full Text] [Related]
17. The Universal 3D3 Antibody of Human PODXL Is Pluripotent Cytotoxic, and Identifies a Residual Population After Extended Differentiation of Pluripotent Stem Cells.
Kang L; Yao C; Khodadadi-Jamayran A; Xu W; Zhang R; Banerjee NS; Chang CW; Chow LT; Townes T; Hu K
Stem Cells Dev; 2016 Apr; 25(7):556-68. PubMed ID: 26886504
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical Analysis Using Antipodocalyxin Monoclonal Antibody PcMab-47 Demonstrates Podocalyxin Expression in Oral Squamous Cell Carcinomas.
Itai S; Yamada S; Kaneko MK; Harada H; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Oct; 36(5):220-223. PubMed ID: 28873000
[TBL] [Abstract][Full Text] [Related]
19. Identification of LEA, a podocalyxin-like glycoprotein, as a predictor for the progression of colorectal cancer.
Yuan D; Chen H; Wang S; Liu F; Cheng Y; Fang J
Cancer Med; 2018 Oct; 7(10):5155-5166. PubMed ID: 30277651
[TBL] [Abstract][Full Text] [Related]
20. Expression of podocalyxin enhances the adherence, migration, and intercellular communication of cells.
Larrucea S; Butta N; Arias-Salgado EG; Alonso-Martin S; Ayuso MS; Parrilla R
Exp Cell Res; 2008 Jun; 314(10):2004-15. PubMed ID: 18456258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
